SCHEMBL15069249

SCHEMBL15069249

Cc1cccc2oc(=O)c(N3CCC3)c(N3CCCCC3)c12

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.49
ALDH1A1 P00352 6/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 3/20 0.48
LMNA P02545 2/20 0.48
HTT P42858 2/20 0.48
TSHR P16473 2/20 0.48
HSD17B10 Q99714 1/20 0.48
AGTR1 P30556 1/20 0.47
MAPT P10636 3/20 0.44
CCR4 P51679 1/20 0.44
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
ELANE P08246 1/20 0.39
MTHFD2 P13995 1/20 0.39
PRKDC P78527 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15069107 0.75 CCR4 (0.49) KMT2AMAPTCCR4ELANEMTHFD2
SCHEMBL15068641 0.72 MAPT (0.46) GAAALDH1A1KMT2AMEN1LMNA
SCHEMBL11922737 0.71 ALDH1A1 (0.65) GAAALDH1A1KMT2AMEN1LMNA
SCHEMBL15068516 0.70 CCR4 (0.41) ALDH1A1KMT2AMEN1LMNAHTT
SCHEMBL15462283 0.69 ALDH1A1 (0.61) GAAALDH1A1KMT2AMEN1LMNA
SCHEMBL6993468 0.68 KDM4E (0.48) GAAALDH1A1HSD17B10MAPTELANE
SCHEMBL15069251 0.67 ALDH1A1 (0.55) GAAALDH1A1KMT2AMEN1LMNA
SCHEMBL15068746 0.65 ALDH1A1 (0.49) GAAALDH1A1KMT2AMEN1LMNA
SCHEMBL20886785 0.64 ALDH1A1 (0.59) ALDH1A1KMT2AMEN1LMNAHTT
SCHEMBL22686228 0.64 ALDH1A1 (0.51) GAAALDH1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 GAA 447/4885ALDH1A1 1006/4885KMT2A 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.